There    are    several    words    to    describe    Dr.    Christopher    Boone:    health    futurist,    social    entrepreneur,    executive,    professor,    patient    advocate,    and    self-proclaimed    “data    hippie.”    Boone    is    recognized    as    being    a    dynamic,   ...

With nearly 30 years of experience in the biotech/pharmaceutical and medical device industries, Jim Caggiano is committed to advancing therapeutic options that improve the lives of patients. Having spent his career focused on areas of medicine where few or no effective options exist, including...

Dr. Dixit conducted extensive graduate and post-graduate training in Toxicology–Biochemistry with both Indian and US Institutions (Case Western Reserve University, Medical College of Ohio, University of Nebraska) and is board certified in Toxicology from the American Board of Toxicology, Inc. since ...

Peter Emtage serves as the Global Head of Cell Therapy Research at Kite, a Gilead company.  He most recently served as the Chief Scientific Officer at Cell Design Labs. He previously held senior positions at Intrexon, MedImmune and Femta Pharmaceuticals. Peter is an immunologist by training and...

Scott is Director of the Antibody Therapeutics group at GNF. His group is responsible for a broad range of platform activities associated with early to late stage antibody drug discovery. Prior to joining GNF, Scott was Sr. Director and Site Head for Pfizer’s Centers for Therapeutic Innovation...

Brenda Hann is the Director of Clinical Research Operations in the Stanford Cancer Clinical Trials Office at Stanford Cancer Institute.  The Cancer Clinical Trials Office provides central coordination and oversight of clinical staff to ensure consistent processes, regulatory compliance and improved ...

Karin Jooss serves as Chief Scientific Officer of Gritstone Oncology.  Dr. Jooss joined Gritstone from Pfizer, where she served as head of Cancer Immunotherapeutics within the Vaccine Immunotherapeutics department for seven years.  While at Pfizer, she built and led immuno-oncology teams, was a...

Dr. Andrew Korytko is currently group leader in protein engineering at Eli Lilly and Company. He has been with Eli Lilly since 2004 and previously was at Applied Molecular Evolution for a number of years before it became a part of Eli Lilly in 2004. Dr. Korytko has over 25 years of experience in...

Johanna Mercier is President and Head of U.S. Commercial at Bristol-MyersSquibb, a position she assumed in October 2017. Johanna has nationaloversight and financial responsibility of a complex organization delivering $12Bin revenue annually. In this leadership role, Johanna strives to instill a...

Andrea has a BS in Finance, received her MD from  Georgetown Medical School and completed her radiology residency at the University of Pittsburgh. Prior to Merck, she was at GE Health Care, BioClinica, and a biotech company in Silicon Valley. Andrea has been at Merck for 6 years. She and her team...

Fred Ramsdell, PhD, is a veteran biotechnology leader in immunology with nearly three decades of experience. He currently leads the development of collaborative research programs at the Parker Institute for Cancer Immunotherapy as vice president of research.After a fellowship at the National...

Dr Rob Scott is Zimbabwean born and studied medicine at the University of Cape Town. For thirty years Rob has held leadership positions in global Pharma, starting with J&J in South Africa. As the Global Head of CV and Metabolic at Pfizer he was responsible for what was then the world’s largest...

Sanjaya Singh, Ph.D., is the Global Head of Janssen BioTherapeutics (JBIO), the biotherapeutics engine of Janssen Research & Development. He is responsible for leading an organization of more than 300 employees in Spring House, PA, La Jolla, CA and Beerse, Belgium who are exploring new and...

Gary Starling is in the Protein Science Department at Merck Research Laboratories, based in the San Francisco Bay Area.  His career has focused on the Discovery and Early Development of Biologic therapeutics.  He began his career in the BioPharmaceutical industry at Bristol-Myers Squibb PRI working ...